EGFR and non-small cell lung carcinoma: Although amivantamab exhibits significant efficacy in improving the survival outcomes for NSCLC patients with EGFR-sensitive mutations (e.g., exon 19 deletions or L858R mutations), its substantial treatment costs present a major barrier to broad clinical implementation.